Spots Global Cancer Trial Database for Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
Official Title: A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma
Study ID: NCT00634205
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with MM failing after at least one previous chemotherapy regimen including platinum derivatives .
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Pneumology CHR St joseph - Warquignies, Boussu, , Belgium
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet, Brussels, , Belgium
Department of Pneumology Hôpital Ixelles-Molière, Brussels, , Belgium
Department of Pneumology CHU Charleroi, Charleroi, , Belgium
Department of Pneumology Hôpital Saint-Joseph, Gilly, , Belgium
Hôpital Ambroise Paré, Mons, , Belgium
CH Peltzer-La Tourelle, Verviers, , Belgium
Department of Pneumology CHRU Lille, Lille, , France
Contact Details
Name: Thierry Berghmans, MD
Affiliation: European Lung Cancer Working Party
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
